Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has entered into a partnership with Shenzhen-based Innorna Co., Ltd, a platform company focused on delivery platforms for nucleic acid therapeutics. Under the agreement, Macera will leverage Innorna’s mRNA-LNP technology to advance the development of in vivo edited chimeric antigen receptor macrophage (CAR-M) technology based on mRNA-LNP.
The collaboration aims to combine Macera’s expertise in macrophage immunotherapy with Innorna’s advanced mRNA-LNP delivery systems to create innovative treatments. Financial details of the partnership were not disclosed.- Flcube.com
